primary hepatocellular carcinoma
Conditions
Interventions
single group:radiotherapy combined with tislelizumab
Sponsors
Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) locally advanced metastatic or unresectable hepatocellular carcinoma (or both); (2) Had not received systemic/systemic treatment before, and was allowed to receive antiviral treatment at the same time; (3) At least one measurable lesion; (4) It is not suitable for regional treatment (TACE and RFA) or has progressed after treatment; (5) ECOG PS score 0-1; (6) Child-pugh level A in liver function; (7) Adequate blood function (platelet count >= 60 x 10^9/L;Hemoglobin >= 85g/L;International standard ratio of prothrombin time (INR) = 28g/L;Total bilirubin 3 months; (11) Men and women, aged 18 or above; (12) No history of liver radiotherapy and no severe cirrhosis; (13) No history of severe allergy; (14) Accept radiotherapy voluntarily and sign informed consent.
Exclusion criteria
Exclusion criteria: (1) Received molecular targeted therapy, anti-angiogenesis therapy or other systemic therapy in recent 3 months. (2) There is a risk of bleeding or bleeding from autoimmune diseases or untreated diseases of the esophagus, stomach and digestive tract. (3) Other parts, such as the lungs, cardiovascular and cerebrovascular system, gynecology, urinary system, blood system, etc., have higher blood risk. (4) Pregnant or nursing patients. (5) Patients with signs of brain metastasis, hepatic encephalopathy, diseases of the blood system and cardiac insufficiency. (6) Severe complications: extremely high risk hypertension, massive cerebral infarction, massive myocardial infarction, cardiac function >= Grade II, history of mental illness, and severe diabetes. (7) Have a history of severe allergy. (8) Patients with moderate to severe pulmonary dysfunction, silicosis and other pulmonary fibrosis. (9) Patients with moderate to severe hypothyroidism. (10) Patients who could not tolerate the treatment and could not cooperate with the visitors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective remission rate; | — |
Countries
China
Contacts
Public ContactZhang Jianwen
Affiliated Hospital of Southwest Medical University
Outcome results
None listed